Report on ivermectin prophylaxis in a hospital in Argentina showing lower cases for healthcare workers taking ivermectin.
Results have been published in the press
lanacion.com.ar (interim results), and a presentation posted online:
, however there is no formal publication to date.
These results would be expected to receive priority publication due to the predicted impact on the pandemic and confirmation of previous prophylaxis studies. The lack of formal publication suggests a negative publication bias that may be due to politicization in the authors' location.
Note that this prophylaxis study is different to the Vallejos early treatment trial.
This is the
28th of 99 COVID-19 controlled studies for ivermectin, which collectively show efficacy with
p<0.0000000001 (1 in 2 sextillion).
46 studies are RCTs, which show efficacy with
p=0.00000014.
This study is excluded in the after exclusion results of meta
analysis:
minimal details provided.
IVERCOR PREP et al., 20 Dec 2020, retrospective, Argentina, preprint, 1 author, dosage 12mg weekly.
